Affiliation:
1. 1. Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo (SP) Brasil.
2. 2. Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo (SP) Brasil. Recebido: 16 fevereiro 2022.
Abstract
Objective: To evaluate the process of diagnosing patients with malignant pleural mesothelioma (MPM) at a tertiary care hospital. Methods: This was a retrospective study involving patients referred to a tertiary-care cancer center in Brazil between 2009 and 2020. The diagnostic process was divided into four steps: onset of symptoms, referral to a specialist visit, histopathological diagnosis, and beginning of treatment. The intervals between each phase and the factors for delays were evaluated. Data including clinical status, radiological examinations, staging, treatment modalities, and survival outcomes were collected. Results: During the study period, 66 patients (mean age = 64 years) were diagnosed with MPM and underwent treatment. Only 27 (41%) of the patients had knowledge of prior exposure to asbestos. The median number of months (IQR) between the onset of symptoms and the first specialist visit, between the specialist visit and histopathological characterization, and between definite diagnosis and beginning of treatment was, respectively, 6.5 (2.0-11.4), 1.5 (0.6-2.1), and 1.7 (1.2-3.4). The knowledge of prior asbestos exposure was associated with a shorter time to referral to a specialist (median: 214 vs. 120 days; p = 0.04). A substantial number of nondiagnostic procedures and false-negative biopsy results (the majority of which involved the use of Cope needle biopsy) were found to be decisive factors for the length of waiting time. The mean overall survival was 11.9 months. Conclusions: The unfamiliarity of health professionals with MPM and the patient's lack of knowledge of prior asbestos exposure were the major factors to cause a long time interval between the onset of symptoms and beginning of treatment. An overall survival shorter than 1 year is likely to have been due to the aforementioned delays.
Publisher
Sociedade Brasileira de Pneumologia e Tisiologia
Reference28 articles.
1. 1. Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, Le GV, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-518. https://doi.org/10.1289/ehp.1002845
2. 2. The United States Geological Survey (USGS). National Minerals Information Center [homepage on the Internet]. USGS: Reston, VA, USA; [cited 2022 Jan 2]. Minerals Yearbook - 2015 [Adobe Acrobat document, 9 p.]. Available from: https://d9-wret.s3-us-west-2.amazonaws.com/assets/palladium/production/mineral-pubs/asbestos/myb1-2015-asbes.pdf
3. 3. Pedra F. Mortalidade por mesotelioma no Brasil de 1980 a 2010. [thesis] Rio de Janeiro: Escola Nacional de Saúde Pública Sergio Arouca; 2015. https://www.arca.fiocruz.br/handle/icict/34320
4. 4. Ugolini D, Bonassi S, Cristaudo A, Leoncini G, Ratto GB, Neri M. Temporal trend, geographic distribution, and publication quality in asbestos research. Environ Sci Pollut Res Int. 2015;22(9):6957-6967. https://doi.org/10.1007/s11356-014-3925-1
5. 5. Algranti E, Ramos-Bonilla JP, Terracini B, Santana VS, Comba P, Pasetto R, et al. Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective. Ann Glob Health. 2019;85(1):49. https://doi.org/10.5334/aogh.2341
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献